These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 35058596)
21. [Recent progress in the treatment of hematological malignancies. II. Chemotherapy of relapsed and refractory acute myeloid leukemia in adult]. Ohshima T Nihon Naika Gakkai Zasshi; 1989 Jun; 78(6):774-80. PubMed ID: 2794659 [No Abstract] [Full Text] [Related]
22. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Konopleva M; Thall PF; Yi CA; Borthakur G; Coveler A; Bueso-Ramos C; Benito J; Konoplev S; Gu Y; Ravandi F; Jabbour E; Faderl S; Thomas D; Cortes J; Kadia T; Kornblau S; Daver N; Pemmaraju N; Nguyen HQ; Feliu J; Lu H; Wei C; Wilson WR; Melink TJ; Gutheil JC; Andreeff M; Estey EH; Kantarjian H Haematologica; 2015 Jul; 100(7):927-34. PubMed ID: 25682597 [TBL] [Abstract][Full Text] [Related]
23. Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma. Huang LW; Wong SW; Andreadis C; Olin RL Curr Oncol Rep; 2019 Mar; 21(4):35. PubMed ID: 30848394 [TBL] [Abstract][Full Text] [Related]
24. Precision medicine for acute myeloid leukemia. Lai C; Karp JE; Hourigan CS Expert Rev Hematol; 2016 Jan; 9(1):1-3. PubMed ID: 26514194 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models. Corrales-Medina FF; Manton CA; Orlowski RZ; Chandra J Leuk Res; 2015 Mar; 39(3):371-9. PubMed ID: 25612941 [TBL] [Abstract][Full Text] [Related]
26. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Goldberg AD; Atallah E; Rizzieri D; Walter RB; Chung KY; Spira A; Stock W; Tallman MS; Cruz HG; Boni J; Havenith KEG; Chao G; Feingold JM; Wuerthner J; Solh M Leuk Res; 2020 Aug; 95():106385. PubMed ID: 32521310 [TBL] [Abstract][Full Text] [Related]
27. An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. Ferguson P; Hills RK; Grech A; Betteridge S; Kjeldsen L; Dennis M; Vyas P; Goldstone AH; Milligan D; Clark RE; Russell NH; Craddock C; Haematologica; 2016 Nov; 101(11):1351-1358. PubMed ID: 27540133 [TBL] [Abstract][Full Text] [Related]
35. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia. Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434 [TBL] [Abstract][Full Text] [Related]
36. Acute myeloid leukemia arising from polycythemia vera underwent reversion to chronic phase of myeloproliferative neoplasm status post chemotherapy: Biclonal myeloid neoplasms with genomic evidence of a common early hematopoietic progenitor. Zhao Y; Sotolongo G; Deak K; Wang E Hematol Oncol; 2021 Apr; 39(2):254-257. PubMed ID: 33137210 [No Abstract] [Full Text] [Related]
37. Two cases of acute myeloid leukemia evolving into a chronic myelomonocytic leukemia-like state after induction therapy. Iwama A; Miwa A; Suzuki T; Komatsu N; Yoshida M; Suda T; Sakamoto S; Miura Y Intern Med; 1992 Feb; 31(2):214-7. PubMed ID: 1600270 [TBL] [Abstract][Full Text] [Related]
38. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Pemmaraju N; Kantarjian H; Kadia T; Cortes J; Borthakur G; Newberry K; Garcia-Manero G; Ravandi F; Jabbour E; Dellasala S; Pierce S; Verstovsek S Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):171-6. PubMed ID: 25441108 [TBL] [Abstract][Full Text] [Related]
39. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Ravandi F; Ritchie EK; Sayar H; Lancet JE; Craig MD; Vey N; Strickland SA; Schiller GJ; Jabbour E; Erba HP; Pigneux A; Horst HA; Recher C; Klimek VM; Cortes J; Roboz GJ; Odenike O; Thomas X; Havelange V; Maertens J; Derigs HG; Heuser M; Damon L; Powell BL; Gaidano G; Carella AM; Wei A; Hogge D; Craig AR; Fox JA; Ward R; Smith JA; Acton G; Mehta C; Stuart RK; Kantarjian HM Lancet Oncol; 2015 Sep; 16(9):1025-1036. PubMed ID: 26234174 [TBL] [Abstract][Full Text] [Related]
40. MDM2- and FLT3-inhibitors in the treatment of Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]